300 related articles for article (PubMed ID: 14963012)
21. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
23. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
24. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
He D; Falany CN
Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
[TBL] [Abstract][Full Text] [Related]
26. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.
Jung C; Kim RS; Zhang HJ; Lee SJ; Jeng MH
Cancer Res; 2004 Dec; 64(24):9185-92. PubMed ID: 15604291
[TBL] [Abstract][Full Text] [Related]
27. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
28. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status.
Torres JM; Ruiz E; Ortega E
Prostate; 2003 Jun; 56(1):74-9. PubMed ID: 12746849
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
30. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation.
Alimirah F; Chen J; Basrawala Z; Xin H; Choubey D
FEBS Lett; 2006 Apr; 580(9):2294-300. PubMed ID: 16580667
[TBL] [Abstract][Full Text] [Related]
31. Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.
Simanainen U; McNamara K; Gao YR; Handelsman DJ
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1335-43. PubMed ID: 19366880
[TBL] [Abstract][Full Text] [Related]
32. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
33. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
34. Combinatorial androgen receptor targeted therapy for prostate cancer.
Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
[TBL] [Abstract][Full Text] [Related]
35. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
Habib FK; Ross M; Bayne CW; Bollina P; Grigor K; Chapman K
Clin Cancer Res; 2003 May; 9(5):1815-9. PubMed ID: 12738739
[TBL] [Abstract][Full Text] [Related]
36. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
37. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.
Agoulnik IU; Vaid A; Bingman WE; Erdeme H; Frolov A; Smith CL; Ayala G; Ittmann MM; Weigel NL
Cancer Res; 2005 Sep; 65(17):7959-67. PubMed ID: 16140968
[TBL] [Abstract][Full Text] [Related]
38. Region-specific expression of androgen and growth factor pathway genes in the rat epididymis and the effects of dual 5alpha-reductase inhibition.
Henderson NA; Cooke GM; Robaire B
J Endocrinol; 2006 Sep; 190(3):779-91. PubMed ID: 17003279
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
[TBL] [Abstract][Full Text] [Related]
40. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
Titus MA; Gregory CW; Ford OH; Schell MJ; Maygarden SJ; Mohler JL
Clin Cancer Res; 2005 Jun; 11(12):4365-71. PubMed ID: 15958619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
